Corrections:

Guozhong Jiang^1,*, Pengju Wang^2,*, Weiwei Wang¹, Wencai Li¹, Liping Dai³ and Kuisheng Chen¹

¹Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
²Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450052, China
³Institute of Medical and Pharmaceutical Sciences in Zhengzhou University, Zhengzhou 450052, China
^*These authors have contributed equally to this work

Published: March 21, 2023

Copyright: © 2023 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 3, the images of control cells SW620 (3A, upper left panel) and HTC116 (3D, upper left panel) were accidentally switched with each other. The corrected Figure 3, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:21663–21673. DOI: https://doi.org/10.18632/oncotarget.15523

Figure 3: ANXA13 regulates CRC cell invasion in vitro invasion assays. (A) Images showing invasive cells that migrated to the bottom chambers. (B, C) Summary graph showing that ANXA13-overexpression significantly increased the number of invasive cells in SW620 (B) and Rko (C) cells. (D) Images showing invasive cells that migrated to the bottom chambers. (E, F) Summary graph showing that ANXA13 siRNA significantly decreased the number of invasive cells in HCT116 (E) and HT29 (F) cells. Values are mean ± SEM; n = 3; *P < 0.05, **P < 0.01 by unpaired Student’s t test.